This is just to reiterate an announcement about the upcoming new prescribing requirements for Clozapine as of October 12, 2015. The information below is from PDR and more information can be found at the FDA website, http://www.fda.gov/Drugs/DrugSafety/ucm461853.htm
What is the shared Clozapine REMS Program?
What are the key changes to neutropenia monitoring recommendations and treatment algorithm for clozapine?
What do I need to do?
Starting October 12, 2015 – To certify you must:
|The products covered under the Clozapine REMS Program are: Clozaril® (clozapine) tablets, for oral use • Versacloz® (clozapine, USP) oral suspension • Fazaclo® (clozapine USP) orally disintegrating tablets • Approved generic equivalents of these products|